Author:
Bashaw Edward D.,Huang Shiew-Mei,Coté Timothy R.,Pariser Anne R.,Garnett Christine E.,Burckart Gilbert,Zhang Lei,Men Angela Y.,Le Christine D.,Charlab Rosane,Gobburu Jogaro V.,Lesko Lawrence J.
Publisher
Springer Science and Business Media LLC
Subject
Drug Discovery,Pharmacology,General Medicine
Reference6 articles.
1. Braun, M. M. et al. Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years. Nature Rev. Drug Discov. 9, 519–522 (2010).
2. Tambuyzer, E. Rare diseases, orphan drugs and their regulation: questions and misconceptions. Nature Rev. Drug Discov. 9, 921–929 (2010).
3. US FDA. Code of Federal Regulations Title 21: Approval of an Application and an Abbreviated Application. Sec. 314.105 (US Government Printing Office, Washington DC, 2011).
4. Jadhav, P. et al. Leveraging prior quantitative knowledge in guiding pediatric drug development: a case study. Pharm. Stat. 8, 216–224 (2009).
5. Bhattaram, V. A. et al. Impact of pharmacometric reviews on new drug approval and labeling decisions — a survey of 31 new drug applications submitted between 2005 and 2006. Clin. Pharmacol. Ther. 81, 213–221 (2007).
Cited by
25 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献